• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The study for the mechanism of the development of diabetic retinopathy

Research Project

Project/Area Number 09671070
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 内分泌・代謝学
Research InstitutionJICHI MEDICAL SCHOOL

Principal Investigator

KUROKI Masatoshi  Department of Medicine, Jichi medecal school, Associate professor, 医学部, 助教授 (90215096)

Co-Investigator(Kenkyū-buntansha) KAWAKAMI Masanobu  Department of Medicine, Jichi medecal school, Professor, 医学部, 教授 (40161286)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 1998: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1997: ¥1,900,000 (Direct Cost: ¥1,900,000)
KeywordsVEGF / hypoxia / oxidative stress / AGE / IGF-1 / oxidized LDL / NO / 細胞内酸化ストレス / 活性酸素 / アラキドン酸代謝経路
Research Abstract

Vascular endothelial growth factor (VEGF) has been causally linked to many changes including retinal edema, hemorrahge, ischemia, microaneurysm, and neovascularization that are characterized diabetic retinopathy. Hypoxia is considered a functional stimulus for VEGF expression in the diabetic eye. However, the mechanisms of hypoxia-induced VEGE expression is still unknown. We have reported that reactive oxygene intermediates (ROI), superoxide and hydrogen peroxide, increases the VEGF gene expression. Therfore, first in this study, we studied the involvement of oxidative stress in the hypoxia-induced VEGF gene expression. Antioxidant agents inhibited the VEGF expression induced by hypoxia and ROI was suggested to be generated through the activation of the archidonic acid pathway.
VEGF has been reported to be recognized in the retina of eary stage of diabetic retinopathy. Therefore, beside the hypoxia, other stimui also may be operative.
Advanced glycation end products (AGEs) have a causal … More role in the development of diabetic complications and correlate with the onset and severity of retinopathy. AGEs were immunohistochemically detected in the retina, proliferative fibromuscular tissues and iris of diabetic patients, and the concentration of AGEs which was estimated with ELBA significantly increased in the vitreous humor of diabetic patients in comparison with those of normal subjects. Based on these data, we examined the role of AGEs in the induction of retinal gene expression. In vitro, AGEs increased VEGF mRNA and protein in human retinal pigment epithelial cells (RPE) and smooth muscle cells (SMC). AGE-induced increases in VEGF were inhibited by antioxidants. In vivo, AGEs increased VEGF mRNA levels in the rat retina. Clinical observations and laboratory data indicate a pathological link between intraocular neovascularization and insulin-like growth factor-i (IGF-1) which has been reported to be increased in daibetic eye. Our study showed tha IGF-1 increased VEGF mRNA levels through the enhancement of VEGF promotor activity in RPE and SMC.Oxidazed low density lipoprotein (oxLDL) was believed to have a major role of the vascular injury and to be increased in the daibetic condition. Our study showed that lysoposphatidylchoilne (LPC) which is the main component of oxLDL increased VEGF mRNa levels and LPC-induced increase in VEGF were inhibited by antioxidants. These results indicate that elevated AGEs, JGF-1 and oxLDL levels may promote retinal neovascularization in diabetes through increased retinal VEGF gene expression.
Our results in this study showed that VEGF gene expression induced by hypoxia, AGEs and oxLDL is regulated by the intracelluar oxidative stress. Recently nitric oxide (NO) has been reported to prevent the several action of ROL.Our study showed that NO inhibited the VEGF gene expression induced by hypoxia and AGES.This suggests that the nitrites which are used widely may be useful for the treatment of diabetic retinopathy. Less

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (11 results)

All Other

All Publications (11 results)

  • [Publications] Amano S, Kuroki M et al.: "Requirement for vascular endothelial growth factor in wound-related corneal neovascularization." Investigative Ophthalmol Vis Sci. 39. 18-22 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 黒木昌寿: "動脈硬化巣における血管内皮増殖因子の発現とその調節" 動脈硬化. 25. 289-292 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ming Lu, M Kuroki et al.: "Advanced glycation end products increase retinal vascular endothelial growth factorexpression." J Clin Invest. 101. 1219-1224 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Punglia RS, Kuroki M et al.: "Regulation of vascular endothelial growth factor expression by insulin-like growth factor I." Diabetes. 46. 1619-1626 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Pournaras CJ, Miller JW et al.: "Systemic hyperoxia decrease vascular endothelial growth factor gene expression in ischemic primate retina." Arch Ophthalmol. 115. 1553-1558 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Amano S,Kuroki M, Tolentiono M and Adamis AP: "Requirement for vascular endothelial growth factor in wound-related corneal neovascularization." Investigative Ophthalmol Vis Sci.39. 18-22 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kuroki M: "Vascular endothelial growth factor expression in the atherosclerotic lesion." J Jpn Atheroscler Soc. 25. 289-292 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ming Lu, M Kuroki, S Amano, M Tolentino, K,Keough, I Kim, R Bucala and AP Adamis: "Advanced glycation end products increase retinal vascular endothelial growth factorexpression." J Clin Invest. 101. 1219-1224 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Punglia RS,Lu M,Hsu J,Kuroki M,Tolentino MJ,Kenough K,Levy AP,Levy NS,Goldberg MA,D'Amato RJ,Adamis AP: "Regulation of vascular endothelial growth factor expression by insulin-like growth factor I." Diabetes. 46. 1619-1626 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Pournaras CJ,Miller JW,Gragoudas Es, Husain D,Munoz JL,Tolentino MJ,Kuroki M,Adamis AP: "Systemic hyperoxia decrease vascular endothelial growth factor gene expression in ischemic primate retina." Arch Ophthalmol. 115. 1553-1558 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Lu M,Kuroki M et al: "Advanced glycation end products increase retinal vascular endothelial growth factor expression" J Clin Invest. 101. 1219-1224 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi